SAGA Diagnostics AB

04/02/2022

We are SAGA and we work to for cancer patients. Find out more at sagadiagnostics.com

23/12/2021

Happy holidays from all of us at SAGA! We continue on our mission to improve outcomes for patients with cancer, and look forward to delivering exciting results in 2022!

Below is our holiday card with one of our favorite recipes of the season. , which are twirled saffron buns that are tasty warm, or lightly toasted and buttered!

02/11/2021

SAGA is pleased to announce that we have entered into an assay development agreement with the global, science-led biopharmaceutical company (LSE/STO/Nasdaq: AZN).

We will in the course of this agreement develop unique dPCR assays towards undisclosed targets for analyses of tissue samples and .

https://sagadiagnostics.com/saga-diagnostics-enters-into-development-agreement-with-astrazeneca

28/10/2021

SAGA is pleased to welcome two new members, Dr Nuria Seguí Gracia and Dr Lucia Oton Gonzalez, to strengthen our and R&D group and accelerate transformative towards the clinics!

https://sagadiagnostics.com/saga-hires-two-new-scientists-to-strengthen-its-rd-team/

07/10/2021

We are pleased to announce Peter Collins as new CEO! He joins SAGA after successful executive roles at major players in the liquid biopsy field such as Inivata as Chief Business Officer and at Guardant Health as VP Biopharma Business Development, and CBO of Yourgene. Peter was also VP, Head of Diagnostics at GSK for 5 years. Throughout his various executive positions, he has demonstrated a track record of building high performance teams and leading organizations’ commercial growth.

https://sagadiagnostics.com/saga-diagnostics-appoints-peter-collins-as-chief-executive-officer/

LUND, Sweden — /October 7, 2021/ — SAGA Diagnostics AB, (“SAGA”), a leading cancer liquid biopsy and genomic testing company, is pleased to announce the appointment of Peter Collins as Chief Executive Officer.

29/06/2021

SAGA is pleased to announce that it has raised SEK 106 million (€10.5 million) in a Series A2. The round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.

Now we can accelerate commercialization of our cancer technologies to aid more patients sooner!

https://sagadiagnostics.com/saga-diagnostics-raises-sek-106-million-e10-5-million-to-accelerate-commercialization-of-ultrasensitive-cancer-liquid-biopsies/

17/06/2021

SAGA is pleased to announce today an expanded research collaboration with Professor Charles Swanton, at the University College London ( ) Cancer Institute.

Last year, SAGA and UCL entered into a research collaboration on a limited number of patients. With the newly signed agreement, SAGA will utilize its proprietary ultrasensitive SAGAsafe® assays and perform analyses on several hundred clinical tissue samples from the Cancer Research UK-funded UCL-sponsored and PEACE studies.

https://sagadiagnostics.com/saga-expands-research-collaboration-with-university-college-london-cancer-institute/

15/06/2021

SAGA Diagnostics is pleased to announce the successful accreditation of its laboratory in Lund, Sweden! SAGA stands for the highest quality services and reagents.

Granted by , the Swedish Board for Accreditation and Conformity Assessment, ISO 17025 is an international quality management standard used to assess the competency of analytical laboratories.

https://sagadiagnostics.com/saga-diagnostics-achieves-iso-17025-accreditation-by-swedac-for-mutation-testing-services/

14/06/2021

SAGA is expanding once again! We are seeking a talented assay developer scientist! If you want to join a team with great mission to usher in the future of , don't miss this opportunity! Located in beautiful Lund, Sweden.
Applicants must have extensive lab experience with .

Read more and apply at https://sagadiagnostics.com/now-recruiting-molecular-diagnostics-scientist-dpcr/

Follow the instructions from the link above to apply via email. DO NOT APPLY VIA FACEBOOK.

22/04/2021

SAGAsafe dPCR analysis used in new study on ESR1 in published in JNCI Cancer Spectrum! SAGAsafe assays for the ESR1 variants E380Q, D538G, Y537S, Y537N, and Y537G were used to analyze patients that had tumor and germline DNA available.

Read more about it here: https://sagadiagnostics.com/sagasafe-technology-utilized-in-new-study-of-esr1-mutations-in-breast-cancer/

01/04/2021

SAGA is hiring! If you want to join a team with great mission to usher in the future of , don't miss this opportunity! Located in beautiful Lund, Sweden.

Applicants must have extensive lab experience with next-generation .

Read more and apply at https://sagadiagnostics.com/now-recruiting-molecular-diagnostics-scientist-ngs/

Do NOT apply via Facebook. Follow the instructions from the link above.

23/03/2021

SAGA announces the participation in the €6.9 million EU H2020 funded consortium grant, TIGER, together with seven other partners and led by eTheRNA immunotherapies. We shall deliver ultrasensitive diagnostics to support development of an mRNA immunotherapy platform to combat HPV-associated cancers.

https://sagadiagnostics.com/saga-diagnostics-co-financed-in-the-eu-commissions-tiger-grant-of-eur-6-9-million-led-by-etherna-immunotherapies/

LUND, Sweden — /March 23, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the participation in the EU H2020 funded consortium grant TIGER together with sev...